Journals / Respiratory Case Reports / 2018 / Cilt: 7 - Sayı: 2

A Case of Sjögren’s Syndrome-Related Pulmonary Arterial Hypertension Treated with Iloprost and Bosentan Combination Therapy

İloprost ve Bosentan Kombinasyon Tedavisi Uygulanan Bir Sjögren Sendromu İlişkili Pulmoner Hipertansiyon Olgusu

Pages
59–62
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The aim of thismanuscript was to present a case of SS-related PAH(SRP) followed under bosentan and iloprost combination therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Sjögren’s syndrome (SS), which is characterized bylymphocytic infiltration of the exocrine glands, is thesecond most common multisystem autoimmune disease after rheumatoid arthritis.
📊
Key Findings & Data:Pulmonary involvement ranges from 9% to 20% and it usually occurs asan airway disease or interstitial lung disease.
💡
Conclusion & Impact:The aim of thismanuscript was to present a case of SS-related PAH(SRP) followed under bosentan and iloprost combination therapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Sjögren’s syndrome (SS), which is characterized bylymphocytic infiltration of the exocrine glands, is thesecond most common multisystem autoimmune disease after rheumatoid arthritis. Pulmonary involvement ranges from 9% to 20% and it usually occurs asan airway disease or interstitial lung disease. Pulmonary arterial hypertension (PAH) is a very rare condition in SS. In SS-associated PAH, the functional classof patients is usually World Health Organization(WHO) Class III/IV and there is no specific treatmentregimen. In addition to nonspecific medical treatmentfor PAH, treatment of the underlying disease andsupportive therapy are important. The aim of thismanuscript was to present a case of SS-related PAH(SRP) followed under bosentan and iloprost combination therapy.

Özet

Sjögren Sendromu (SS) ekzokrin glandların lenfositik infiltrasyonu ile karakterize, romatoid artritten sonra ikinci en sık görülen multisitem otoimmün hastalıktır. Pulmoner tutulum %9-20 sıklıkta bildirilmiştir ve genellikle hava yolu hastalığı ya da interstisyel akciğer hastalığı şeklinde görülür. Pulmoner Arteriyel Hipertansiyon (PAH) gelişimi SS’da çok nadir bir durumdur. SS ilişkili PAH’da hastalar genellikle fonksiyonel sınıf WHO-III/IV’dür ve spesifik bir tedavi rejimi yoktur. PAH’ın nonspesifik tedavisine ek olarak altta yatan hastalığın tedavisi önemlidir. Bu yazıdaki amacımız iloprost ve bosentan kombinasyon tedavisi altında izlediğimiz bir SS ilişkili PAH (SİP) olgusunu takdim etmektir.

🔖

Cite This Article

OGAN, N., EKİCİ, B., BAHA, A., AKPINAR, E. E. (2022). A Case of Sjögren’s Syndrome-Related Pulmonary Arterial Hypertension Treated with Iloprost and Bosentan Combination Therapy. Respiratory Case Reports, Cilt: 7 - Sayı: 2, 59–62. https://ajindex.com/articles/588984

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Flament T, Bigot A, Chaigne B, Henique H, Diot E, Marchand-Adam S. Pulmonary manifestations of Sjögren’s Syndrome. Eur Respir Rev 2016; 25:110–23. [CrossRef] 2. Launay D, Hachulla E, Hatron PY, Jais X, Simonneau G, Humbert M. Pulmonary arterial hypertension: a rare complication of primary Sjogren Syndrome report of 9 new cases and review of the literature. Medicine (Baltimore) 2007; 86:299-315. 3. Fujita T1, Tanabe N, Kasahara Y, Sugiura T, Sakao S, Tatsumi K. Withdrawal of epoprostenol therapy in a patient with pulmonary hypertension associated with Sjögren’s syndrome. Intern Med 2014; 53:2237-40 4. Guerreso K, Conner EA. Possible role of anti-SSA/Ro antibodies in the pathogenesis of pulmonary hypertension. Respir Med Case Rep 2016; 17:47-9. [CrossRef] 5. Zhao J, Wang Q, Liu Y, Tian Z, Guo X, Wang H, et al. Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: A cohort study in China. Int J Cardiol 2017; 236:432–7. [CrossRef] 6. Hwang JA, Yang TH, Lee JY, Koo DW, Choi IS, Cho SY, et al. Severe pulmonary hypertension in primary Sjögren’s syndrome. Korean Circ J 2013; 43:504-7. [CrossRef] 7. YJ Hao, X Jiang, W Zhou, Wang Y, Gao L, Wang Y et al. Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients. Eur Respir J 2014; 44:963–72. [CrossRef] 8. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179:151 -7. [CrossRef] 9. Kokosi M, Riemer EC, Highland KB. Pulmonary involvement in Sjögren syndrome. Clin Chest Med 2010; 31:489-500. [CrossRef]